Mabthera 500MG Injection (50ml), containing the active ingredient Rituximab, is a monoclonal antibody used primarily in the treatment of certain types of cancers and autoimmune diseases. This medication is designed to target and deplete CD20-positive B cells, which are implicated in various malignancies and immune disorders. Mabthera is commonly prescribed for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, among others. The injection is administered intravenously, allowing for direct delivery into the bloodstream, which enhances its efficacy. Each vial contains 500mg of Rituximab, and the formulation is designed to ensure stability and effectiveness. As a targeted therapy, Mabthera represents a significant advancement in the treatment landscape, offering patients a tailored approach to managing their conditions.